Skip to content
Chlorzoxazone
Paraflex, Parafon, Strifon (chlorzoxazone) is a small molecule pharmaceutical. Chlorzoxazone was first approved as Paraflex on 1982-01-01. It is used to treat muscle cramp, muscle rigidity, myositis, pain, and spasm in the USA. It is known to target intermediate conductance calcium-activated potassium channel protein 4 and small conductance calcium-activated potassium channel protein 2.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
nervous system diseasesD009422
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Chlorzoxazone
Tradename
Company
Number
Date
Products
PARAFON FORTE DSCJohnson & JohnsonN-011529 DISCN1987-06-15
1 products, RLD
PARAFLEXJohnson & JohnsonN-011300 DISCN1982-01-01
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
chlorzoxazoneANDA2023-06-09
parafon dscANDA2010-02-09
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
muscle crampHP_0003394D009120
muscle rigidityHP_0002063D009127
myositisEFO_0000783D009220G72.49
painEFO_0003843D010146R52
spasmD013035M62.83
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
M: Musculo-skeletal system drugs
M03: Muscle relaxants
M03B: Muscle relaxants, centrally acting agents
M03BB: Oxazol, thiazine, and triazine derivatives centrally acting muscle relaxants
M03BB03: Chlorzoxazone
M03BB53: Chlorzoxazone, combinations excl. psycholeptics
M03BB73: Chlorzoxazone, combinations with psycholeptics
HCPCS
No data
Clinical
Clinical Trials
70 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypertensionD006973EFO_0000537I10451713644
Essential hypertensionD000075222I105117
Chronic renal insufficiencyD051436N18235
Left ventricular hypertrophyD017379EFO_000389622
Heart failureD006333EFO_0003144I50112
Cardio-renal syndromeD059347112
Aortic valve stenosisD001024EFO_0000266Q25.111
Aortic valve insufficiencyD001022EFO_000714811
Metabolic syndromeD024821EFO_0000195E88.8111
OverweightD050177E66.311
Show 1 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiovascular diseasesD002318EFO_0000319I9827110
Heart diseasesD006331EFO_0003777I51.92518
Healthy volunteers/patients213
Vascular diseasesD014652EFO_0004264I77213
Myocardial infarctionD009203EFO_0000612I21112
Coronary diseaseD003327112
Sleep apnea syndromesD012891EFO_0003877G47.311
Kidney transplantationD01603011
HypercholesterolemiaD006937HP_000312411
Diabetes mellitusD003920EFO_0000400E08-E1311
Show 5 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 1 diabetes mellitusD003922EFO_0001359E1011
HypercalciuriaD053565R82.99411
Renal insufficiencyD051437HP_0000083N1911
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ambulatory blood pressure monitoringD01866011
Vascular stiffnessD05928911
Kidney calculiD007669EFO_0004253N20.011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCHLORZOXAZONE
INNchlorzoxazone
Description
Chlorzoxazone is a member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm. It has a role as a muscle relaxant and a sedative. It is a member of 1,3-benzoxazoles, an organochlorine compound and a heteroaryl hydroxy compound.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=c1[nH]c2cc(Cl)ccc2o1
Identifiers
PDB1M8D
CAS-ID95-25-0
RxCUI2410
ChEMBL IDCHEMBL1371
ChEBI ID3655
PubChem CID2733
DrugBankDB00356
UNII IDH0DE420U8G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
KCNN4
KCNN4
KCNN2
KCNN2
Organism
Homo sapiens
Gene name
KCNN4
Gene synonyms
IK1, IKCA1, KCA4, SK4
NCBI Gene ID
Protein name
intermediate conductance calcium-activated potassium channel protein 4
Protein synonyms
IK1, IKCa1, intermediate-conductance Ca2+-activated K+ channel, KCa3.1, KCa3.1, KCa4, potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4, potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4, putative erythrocyte intermediate conductance calcium-activated potassium Gardos channel, Putative Gardos channel, SKCa 4, SKCa4, small conductance calcium-activated potassium channel 4
Uniprot ID
Mouse ortholog
Kcnn4 (16534)
intermediate conductance calcium-activated potassium channel protein 4 (Q9CY39)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,377 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
2,843 adverse events reported
View more details